UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.294

Sortiert nach

Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4

Acta neuropathologica, 2024-07, Vol.148 (1), p.12, Article 12

2024

Volltextzugriff (PDF)

Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients

Annals of hematology, 2023-05, Vol.102 (5), p.1203-1213

2023

Volltextzugriff (PDF)

Cerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment

Annals of oncology, 2018-10, Vol.29, p.viii426-viii426

2018

Volltextzugriff (PDF)

The impact of etiology in lesion-symptom mapping – A direct comparison between tumor and stroke

NeuroImage clinical, 2023-01, Vol.37, p.103305-103305, Article 103305

2023

Volltextzugriff (PDF)

Automatic identification of atypical clinical fMRI results

Neuroradiology, 2020-12, Vol.62 (12), p.1677-1688

2020

Volltextzugriff (PDF)

The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma

Journal of neuro-oncology, 2015-10, Vol.125 (1), p.167-175

2015

Volltextzugriff (PDF)

Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration

Cardiovascular and interventional radiology, 2019-11, Vol.42 (11), p.1649-1652

2019

Volltextzugriff (PDF)

Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white matter and grey matter volume with increasing dose

Clinical and translational radiation oncology, 2021-11, Vol.31, p.14-20

2021

Volltextzugriff (PDF)

Correction to: Automatic identification of atypical clinical fMRI results

Neuroradiology, 2020-12, Vol.62 (12), p.1723-1723

2020

Volltextzugriff (PDF)

Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide

Netherlands journal of medicine, 2017-12, Vol.75 (10), p.451-454

2017

Volltextzugriff (PDF)

Attentional modulation fails to attenuate the subjective pain experience in chronic, unexplained pain

European journal of pain, 2010-03, Vol.14 (3), p.282.e1-282.e10

2010

Volltextzugriff (PDF)

Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities

Journal of neurology, 2012-06, Vol.259 (6), p.1231-1233

2012

Volltextzugriff (PDF)

Stability of a chronic implanted brain-computer interface in late-stage amyotrophic lateral sclerosis

Clinical neurophysiology, 2019-10, Vol.130 (10), p.1798-1803

2019

Volltextzugriff (PDF)

Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates

PloS one, 2019-10, Vol.14 (10), p.e0222717-e0222717

2019

Volltextzugriff (PDF)

P11.51.B STATUS EPILEPTICUS IN WHO GRADE 2 AND 3 DIFFUSE GLIOMA - PREVALENCE AND PREDICTORS

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii85-ii85

2023

Volltextzugriff (PDF)

P11.11.A VOLUMETRIC AND SPATIAL ANALYSES OF TREATMENT-RELATED INJURY IN GLIOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii74-ii74

2023

Volltextzugriff (PDF)

OS06.6.A FLAIR-SIGNAL INTENSITY CHANGE AS A PREDICTOR OF PROGRESSIVE GLIOBLASTOMA IN THE EORTC CENTRIC AND CORE STUDIES

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii17-ii18

2023

Volltextzugriff (PDF)

Will {sup 177}Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration

Cardiovascular and interventional radiology, 2019-11, Vol.42 (11)

2019

Volltextzugriff (PDF)

1197PCerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P17.19.B Incidence of treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma treated with cilengitide (EORTC 26071 - CENTRIC study): interim analysis

Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii93-ii93

2022

Volltextzugriff (PDF)

OS06.5.A CLINICAL AND LOCATION-SPECIFIC DETERMINANTS TO DISTINGUISH TUMOR PROGRESSION FROM TREATMENT-INDUCED EFFECTS IN HIGH GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii17-ii17

2023

Volltextzugriff (PDF)

KS04.6.A Epidemiology of adult meningioma in the Netherlands: a population-based study

Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii5-ii5

2022

Volltextzugriff (PDF)

P13.10 Glioblastoma within the subventricular zone associates with increased mesenchymal transition: an intratumoral gene expression analysis

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii64-iii64

2019

Volltextzugriff (PDF)

P14.30 Voxelwise analysis of spatial distribution of postoperative ischemia in diffuse glioma

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii44-ii44

2021

Volltextzugriff (PDF)

P14.23 Relation between neurological deficits and location of postsurgical ischemia in glioma resection

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii42-ii42

2021

Volltextzugriff (PDF)

1 – 25 von 2.294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.063)
Mit Volltextzugriff
(2.036)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4

Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients

Cerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment

The impact of etiology in lesion-symptom mapping – A direct comparison between tumor and stroke

Automatic identification of atypical clinical fMRI results

The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma

Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration

Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white matter and grey matter volume with increasing dose

Correction to: Automatic identification of atypical clinical fMRI results

Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide

Attentional modulation fails to attenuate the subjective pain experience in chronic, unexplained pain

Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities

Stability of a chronic implanted brain-computer interface in late-stage amyotrophic lateral sclerosis

Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates

P11.51.B STATUS EPILEPTICUS IN WHO GRADE 2 AND 3 DIFFUSE GLIOMA - PREVALENCE AND PREDICTORS

P11.11.A VOLUMETRIC AND SPATIAL ANALYSES OF TREATMENT-RELATED INJURY IN GLIOMA

OS06.6.A FLAIR-SIGNAL INTENSITY CHANGE AS A PREDICTOR OF PROGRESSIVE GLIOBLASTOMA IN THE EORTC CENTRIC AND CORE STUDIES

Will {sup 177}Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration

1197PCerebrospinal fluid lymphocytosis: A hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment

P17.19.B Incidence of treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma treated with cilengitide (EORTC 26071 - CENTRIC study): interim analysis

OS06.5.A CLINICAL AND LOCATION-SPECIFIC DETERMINANTS TO DISTINGUISH TUMOR PROGRESSION FROM TREATMENT-INDUCED EFFECTS IN HIGH GRADE GLIOMA

KS04.6.A Epidemiology of adult meningioma in the Netherlands: a population-based study

P13.10 Glioblastoma within the subventricular zone associates with increased mesenchymal transition: an intratumoral gene expression analysis

P14.30 Voxelwise analysis of spatial distribution of postoperative ischemia in diffuse glioma

P14.23 Relation between neurological deficits and location of postsurgical ischemia in glioma resection

Suchergebnisse filtern